India's semaglutide patent is scheduled to expire on March 20, allowing for the introduction of approximately 50 branded generics into the market.
This development could enhance the accessibility of weight-loss medications, potentially increasing treatment options for obesity on a global scale.
The influx of generics may also lead to competitive pricing, influencing market dynamics and healthcare strategies in various regions.